According to studies published in previous years, the angiopoietin system (ANG), consisting of angiopoietin 1 (ANG1) and angiopoietin 2 (ANG2) antagonists, could be involved in both disease staging and treatment response in patients with IPAH [87]. Here, ANGPT1 is linked to idiopathic pulmonary arterial hypertension.